SBFM
Sunshine Biopharma·NASDAQ
--
--(--)
--
--(--)
SBFM fundamentals
Sunshine Biopharma (SBFM) released its earnings on Aug 12, 2025: revenue was 9.41M (YoY +1.15%), missed estimates; EPS was -0.39 (YoY +96.08%), missed estimates.
Revenue / YoY
9.41M
+1.15%
EPS / YoY
-0.39
+96.08%
Report date
Aug 12, 2025
EPS
Revenue
Revenue & Expenses
SBFM has released its 2025 Q3 earnings report, with revenue of 9.42M, reflecting a YoY change of 11.64%, and net profit of -883.82K, showing a YoY change of 26.21%. The Sankey diagram below clearly presents SBFM's revenue sources and cost distribution.
Key Indicators
Sunshine Biopharma (SBFM) key financial stats and ratios, covering profitability, financial health, and leverage.
Sunshine Biopharma (SBFM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Sunshine Biopharma (SBFM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Sunshine Biopharma (SBFM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Sunshine Biopharma (SBFM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Sunshine Biopharma (SBFM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What factors drove the changes in Sunshine Biopharma's revenue and profit?What were the key takeaways from Sunshine Biopharma’s earnings call?What is Sunshine Biopharma's gross profit margin?What is Sunshine Biopharma's latest dividend and current dividend yield?Did Sunshine Biopharma beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Sunshine Biopharma year over year?What is the market's earnings forecast for Sunshine Biopharma next quarter?What were the key takeaways from Sunshine Biopharma's earnings call?
